AIMS/HYPOTHESIS: Plasminogen activator inhibitor-1 (PAI-1) has been regarded as the main antifibrinolytic protein in diabetes, but recent work indicates that complement C3 (C3), an inflammatory protein, directly compromises fibrinolysis in type 1 diabetes. The aim of the current project was to investigate associations between C3 and fibrinolysis in a large cohort of individuals with type 2 diabetes. METHODS: Plasma levels of C3, C-reactive protein (CRP), PAI-1 and fibrinogen were analysed by ELISA in 837 patients enrolled in the Edinburgh Type 2 Diabetes Study. Fibrin clot lysis was analysed using a validated turbidimetric assay. RESULTS: Clot lysis time correlated with C3 and PAI-1 plasma levels (r = 0.24, p < 0.001 and r = 0.22, p < 0.001, respectively). In a multivariable regression model involving age, sex, BMI, C3, PAI-1, CRP and fibrinogen, and using log-transformed data as appropriate, C3 was associated with clot lysis time (regression coefficient 0.227 [95% CI 0.161, 0.292], p < 0.001), as was PAI-1 (regression coefficient 0.033 [95% CI 0.020, 0.064], p < 0.05) but not fibrinogen (regression coefficient 0.003 [95% CI -0.046, 0.051], p = 0.92) or CRP (regression coefficient 0.024 [95% CI -0.008, 0.056], p = 0.14). No correlation was demonstrated between plasma levels of C3 and PAI-1 (r = -0.03, p = 0.44), consistent with previous observations that the two proteins affect different pathways in the fibrinolytic system. CONCLUSIONS/ INTERPRETATION: Similarly to PAI-1, C3 plasma levels are independently associated with fibrin clot lysis in individuals with type 2 diabetes. Therefore, future studies should analyse C3 plasma levels as a surrogate marker of fibrinolysis potential in this population.
AIMS/HYPOTHESIS: Plasminogen activator inhibitor-1 (PAI-1) has been regarded as the main antifibrinolytic protein in diabetes, but recent work indicates that complement C3 (C3), an inflammatory protein, directly compromises fibrinolysis in type 1 diabetes. The aim of the current project was to investigate associations between C3 and fibrinolysis in a large cohort of individuals with type 2 diabetes. METHODS: Plasma levels of C3, C-reactive protein (CRP), PAI-1 and fibrinogen were analysed by ELISA in 837 patients enrolled in the Edinburgh Type 2 Diabetes Study. Fibrin clot lysis was analysed using a validated turbidimetric assay. RESULTS: Clot lysis time correlated with C3 and PAI-1 plasma levels (r = 0.24, p < 0.001 and r = 0.22, p < 0.001, respectively). In a multivariable regression model involving age, sex, BMI, C3, PAI-1, CRP and fibrinogen, and using log-transformed data as appropriate, C3 was associated with clot lysis time (regression coefficient 0.227 [95% CI 0.161, 0.292], p < 0.001), as was PAI-1 (regression coefficient 0.033 [95% CI 0.020, 0.064], p < 0.05) but not fibrinogen (regression coefficient 0.003 [95% CI -0.046, 0.051], p = 0.92) or CRP (regression coefficient 0.024 [95% CI -0.008, 0.056], p = 0.14). No correlation was demonstrated between plasma levels of C3 and PAI-1 (r = -0.03, p = 0.44), consistent with previous observations that the two proteins affect different pathways in the fibrinolytic system. CONCLUSIONS/ INTERPRETATION: Similarly to PAI-1, C3 plasma levels are independently associated with fibrin clot lysis in individuals with type 2 diabetes. Therefore, future studies should analyse C3 plasma levels as a surrogate marker of fibrinolysis potential in this population.
Authors: Umme Amara; Michael A Flierl; Daniel Rittirsch; Andreas Klos; Hui Chen; Barbara Acker; Uwe B Brückner; Bo Nilsson; Florian Gebhard; John D Lambris; Markus Huber-Lang Journal: J Immunol Date: 2010-09-24 Impact factor: 5.422
Authors: Saad H Alzahrani; Katharina Hess; Jackie F Price; Mark Strachan; Paul D Baxter; Richard Cubbon; Fladia Phoenix; T Gamlen; R A S Ariëns; Peter J Grant; Ramzi A Ajjan Journal: J Clin Endocrinol Metab Date: 2012-09-20 Impact factor: 5.958
Authors: K Hess; S H Alzahrani; M Mathai; V Schroeder; A M Carter; G Howell; T Koko; M W J Strachan; J F Price; K A Smith; P J Grant; R A Ajjan Journal: Diabetologia Date: 2011-09-15 Impact factor: 10.122
Authors: Jackie F Price; Rebecca M Reynolds; Rory J Mitchell; Rachel M Williamson; F Gerald R Fowkes; Ian J Deary; Amanda J Lee; Brian M Frier; Peter C Hayes; Mark W J Strachan Journal: BMC Endocr Disord Date: 2008-12-11 Impact factor: 2.763
Authors: Katharina Schuett; Anna Savvaidis; Sebastian Maxeiner; Katharina Lysaja; Vera Jankowski; Stephan H Schirmer; Nada Dimkovic; Peter Boor; Nadine Kaesler; Friedo W Dekker; Jürgen Floege; Nikolaus Marx; Georg Schlieper Journal: J Am Soc Nephrol Date: 2017-01-05 Impact factor: 10.121
Authors: William A E Parker; Rachel C Orme; Jessica Hanson; Hannah M Stokes; Claire M Bridge; Patricia A Shaw; Wael Sumaya; Kirstie Thorneycroft; Giovanna Petrucci; Benedetta Porro; Heather M Judge; Ramzi A Ajjan; Bianca Rocca; Robert F Storey Journal: Platelets Date: 2019-02-13 Impact factor: 3.862
Authors: William A E Parker; Christian Schulte; Temo Barwari; Fladia Phoenix; Sam M Pearson; Manuel Mayr; Peter J Grant; Robert F Storey; Ramzi A Ajjan Journal: Cardiovasc Diabetol Date: 2020-01-07 Impact factor: 9.951
Authors: Wael Sumaya; Lars Wallentin; Stefan K James; Agneta Siegbahn; Katja Gabrysch; Maria Bertilsson; Anders Himmelmann; Ramzi A Ajjan; Robert F Storey Journal: Eur Heart J Date: 2018-04-01 Impact factor: 29.983